Renal

Numbers growing among younger people, urgent action and more therapies needed

The burden of kidney disease continues to grow among Malaysians, especially among younger people, compounded by a rise in related diseases, necessitating action to mitigate the issue and creating a need for new therapies to help patients.

Over

51,000

Patients with End-Stage renal Disease in Malaysia, with 10,000 new diagnoses annually. 1

A silent killer

Early screening for high-risk groups, especially those with diabetes and hypertension, is important for intervention to delay the progression of the disease.

Patients will need dialysis
0
SOCSO spend on dialysis in 2022.
Compared with RM1.22m in 1999
RM 0 million
Cost to healthcare system (ESRD and CKD)
RM 0 billion
65

The primary driver of the surge in chronic kidney disease is the increase in non-communicable diseases, particularly diabetes. Malaysia has consistently remained among the top three countries in the world with the highest proportion of new end stage kidney disease patients having diabetes as the primary cause, at 65%.3

Our Therapies

There is a demand for effective therapies that can help Malaysians with kidney disease maintain better quality of life. Our portfolio of specialty pharmaceutical drugs for the domestic and international market to treat kidney disease, includes Unihepa, Ranofer, Erysaa®, Bi-haemosol and Haemosol.
ethical-specialty-ranofer
ethical-specialty-erysaa
ethical-specialty-haemosol
ethical-specialty-bi-haemosol
ethical-specialty-unihepa

References

  1. Malaysia Is On The Brink Of A Kidney Disease Crisis — Galen Centre For Health And Social Policy
  2. New Straits Times Online, 10 March 2022, ‘Only 5 per cent of chronic kidney disease patients are aware of it’
  3. Ministry of Health Malaysia. 2018. National Action Plan for Healthy Kidneys (ACT-KID) 2018-2025.